Vaccines designed for SARS-CoV-2 are known to be effective against COVID-19 by targeting the surface glycoprotein (S protein) or the receptor-binding domain (RBD) protein located within the S protein [8,9,10,11,12]. The gene discussed is PROS1; the disease is COVID-19.